Inovio Pharmaceuticals(US:INO) Globenewswire·2026-01-20 21:08Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Inovio Pharmaceuticals and its officers/directors, following a significant stock price drop after FDA news regarding its drug application [1][3][4]. Group 1: Investigation Details - Pomerantz LLP is representing investors of Inovio Pharmaceuticals, urging them to contact the firm regarding potential claims [1]. - The investigation focuses on whether Inovio and its executives have engaged in securities fraud or other unlawful practices [1]. Group 2: FDA Announcement and Stock Impact - On December 29, 2025, the FDA accepted Inovio's Biologics License Application for INO-3107 but indicated that the company did not provide sufficient information for accelerated approval [3]. - Inovio announced it would not pursue approval under the standard review timeline and plans to meet with the FDA to discuss options for accelerated approval [3]. - Following this announcement, Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share [4].